FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006941819> ?p ?o ?g. }

• W3006941819 endingPage "561" @default.
• W3006941819 startingPage "561" @default.
• W3006941819 abstract "<h3>Importance</h3> Several randomized clinical trials have recently established the safety and efficacy of endovascular treatment (EVT) of acute ischemic stroke in the anterior circulation. However, it remains uncertain whether patients with acute basilar artery occlusion (BAO) benefit from EVT. <h3>Objective</h3> To evaluate the association between EVT and clinical outcomes of patients with acute BAO. <h3>Design, Setting, and Participants</h3> This nonrandomized cohort study, the EVT for Acute Basilar Artery Occlusion Study (BASILAR) study, was a nationwide prospective registry of consecutive patients presenting with an acute, symptomatic, radiologically confirmed BAO to 47 comprehensive stroke centers across 15 provinces in China between January 2014 and May 2019. Patients with acute BAO within 24 hours of estimated occlusion time were divided into groups receiving standard medical treatment plus EVT or standard medical treatment alone. <h3>Main Outcomes and Measures</h3> The primary outcome was the improvement in modified Rankin Scale scores (range, 0 to 6 points, with higher scores indicating greater disability) at 90 days across the 2 groups assessed as a common odds ratio using ordinal logistic regression shift analysis, adjusted for prespecified prognostic factors. The secondary efficacy outcome was the rate of favorable functional outcomes defined as modified Rankin Scale scores of 3 or less (indicating an ability to walk unassisted) at 90 days. Safety outcomes included symptomatic intracerebral hemorrhage and 90-day mortality. <h3>Results</h3> A total of 1254 patients were assessed, and 829 patients (of whom 612 were men [73.8%]; median [interquartile] age, 65 [57-74] years) were recruited into the study. Of these, 647 were treated with standard medical treatment plus EVT and 182 with standard medical treatment alone. Ninety-day functional outcomes were substantially improved by EVT (adjusted common odds ratio, 3.08 [95% CI, 2.09-4.55];<i>P</i> < .001). Moreover, EVT was associated with a significantly higher rate of 90-day modified Rankin Scale scores of 3 or less (adjusted odds ratio, 4.70 [95% CI, 2.53-8.75];<i>P</i> < .001) and a lower rate of 90-day mortality (adjusted odds ratio, 2.93 [95% CI, 1.95-4.40];<i>P</i> < .001) despite an increase in symptomatic intracerebral hemorrhage (45 of 636 patients [7.1%] vs 1 of 182 patients [0.5%];<i>P</i> < .001). <h3>Conclusions and Relevance</h3> Among patients with acute BAO, EVT administered within 24 hours of estimated occlusion time is associated with better functional outcomes and reduced mortality." @default.
• W3006941819 created "2020-03-06" @default.
• W3006941819 creator A5000432967 @default.
• W3006941819 creator A5000546663 @default.
• W3006941819 creator A5002706809 @default.
• W3006941819 creator A5004019574 @default.
• W3006941819 creator A5005544909 @default.
• W3006941819 creator A5006634321 @default.
• W3006941819 creator A5006722745 @default.
• W3006941819 creator A5008217251 @default.
• W3006941819 creator A5008974275 @default.
• W3006941819 creator A5011428948 @default.
• W3006941819 creator A5012278873 @default.
• W3006941819 creator A5013092972 @default.
• W3006941819 creator A5013896850 @default.
• W3006941819 creator A5015650979 @default.
• W3006941819 creator A5015726521 @default.
• W3006941819 creator A5015971780 @default.
• W3006941819 creator A5018005107 @default.
• W3006941819 creator A5019524203 @default.
• W3006941819 creator A5020412286 @default.
• W3006941819 creator A5022506087 @default.
• W3006941819 creator A5026144170 @default.
• W3006941819 creator A5026241168 @default.
• W3006941819 creator A5026427868 @default.
• W3006941819 creator A5027150115 @default.
• W3006941819 creator A5032931579 @default.
• W3006941819 creator A5039075115 @default.
• W3006941819 creator A5040078390 @default.
• W3006941819 creator A5042070366 @default.
• W3006941819 creator A5045259974 @default.
• W3006941819 creator A5047815573 @default.
• W3006941819 creator A5048303425 @default.
• W3006941819 creator A5050043022 @default.
• W3006941819 creator A5051644936 @default.
• W3006941819 creator A5056455324 @default.
• W3006941819 creator A5059164159 @default.
• W3006941819 creator A5060440166 @default.
• W3006941819 creator A5060959478 @default.
• W3006941819 creator A5064640873 @default.
• W3006941819 creator A5064899054 @default.
• W3006941819 creator A5065058975 @default.
• W3006941819 creator A5065155009 @default.
• W3006941819 creator A5065588215 @default.
• W3006941819 creator A5067327146 @default.
• W3006941819 creator A5068229946 @default.
• W3006941819 creator A5068922999 @default.
• W3006941819 creator A5070031492 @default.
• W3006941819 creator A5070046055 @default.
• W3006941819 creator A5070578002 @default.
• W3006941819 creator A5071976622 @default.
• W3006941819 creator A5073606624 @default.
• W3006941819 creator A5075816868 @default.
• W3006941819 creator A5077676007 @default.
• W3006941819 creator A5078882383 @default.
• W3006941819 creator A5080010553 @default.
• W3006941819 creator A5082283868 @default.
• W3006941819 creator A5083275305 @default.
• W3006941819 creator A5083822364 @default.
• W3006941819 creator A5084685500 @default.
• W3006941819 creator A5084866770 @default.
• W3006941819 creator A5086744674 @default.
• W3006941819 date "2020-05-01" @default.
• W3006941819 modified "2023-10-16" @default.
• W3006941819 title "Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry" @default.
• W3006941819 cites W1969661146 @default.
• W3006941819 cites W2013064866 @default.
• W3006941819 cites W2014796100 @default.
• W3006941819 cites W2037399775 @default.
• W3006941819 cites W2050880768 @default.
• W3006941819 cites W2068190131 @default.
• W3006941819 cites W2080504768 @default.
• W3006941819 cites W2097822359 @default.
• W3006941819 cites W2105486230 @default.
• W3006941819 cites W2111177859 @default.
• W3006941819 cites W2111559905 @default.
• W3006941819 cites W2114603310 @default.
• W3006941819 cites W2114676241 @default.
• W3006941819 cites W2117855158 @default.
• W3006941819 cites W2119542322 @default.
• W3006941819 cites W2122442936 @default.
• W3006941819 cites W2122532950 @default.
• W3006941819 cites W2134066226 @default.
• W3006941819 cites W2138595885 @default.
• W3006941819 cites W2139621750 @default.
• W3006941819 cites W2139703299 @default.
• W3006941819 cites W2143237216 @default.
• W3006941819 cites W2153664287 @default.
• W3006941819 cites W2156287977 @default.
• W3006941819 cites W2171058244 @default.
• W3006941819 cites W2253606929 @default.
• W3006941819 cites W2278166833 @default.
• W3006941819 cites W2511388967 @default.
• W3006941819 cites W2516224652 @default.
• W3006941819 cites W2600513978 @default.
• W3006941819 cites W2766156151 @default.
• W3006941819 cites W2767776410 @default.
• W3006941819 cites W2784144747 @default.

• next